Effect of Covid-19 on Hypertension

The Long-term Impact of COVID-19 on Blood Pressure: A Retrospective Cohort Study

In this single center , retrospective study, 5355 covid patient were selected from 2020 to 2022, with recorded blood pressure before covid and recording after covid. Blood pressure before and after covid were compared, by pair T test.

Study Overview

• Status: Completed
• Conditions: COVID-19; Hypertension
• Intervention / Treatment: Diagnostic test: blood pressure measurement

Detailed Description

design and participants This single-center retrospective cohort study was conducted at an outpatient cardiology clinic in Shiraz, Iran, between February 15, 2020, and December 28, 2022. We evaluated patients with a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA reverse-transcriptase polymerase-chain-reaction assays from nasopharyngeal or oropharyngeal swab specimens according to World Health Organization guidelines (12). Two physicians (PA, MY) reviewed the patients' electronic medical records, including demographics, comorbidities, vital signs, treatments, and outcomes. Ambiguities were resolved by a third author (MM).

The current study included all COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery. The following patients were excluded: those under 18, with hospital admission due to COVID-19, who received corticosteroid therapy, those with a history of systemic inflammatory disease, kidney or liver, immunocompromised patients, and those who switched their antihypertensive regimen during the study. Finally, 5,355 eligible patients were investigated . The primary outcome was to assess BP variation following infection (particularly a prolonged rise in BP) among non-hospitalized COVID-19 patients. The secondary outcome was to identify the predictor factors of BP variation.

The present study was approved by the Ethics Committee of Shiraz University of Medical Sciences under code IR.SUMS.MED.REC.1401.465 , and the need for informed consent was waived due to the study's retrospective nature and the absence of patient identifiers in the presented data.

• Study Type: Observational
• Enrollment (Actual): 5355

Contacts and Locations

Study Locations

• Iran, Islamic Republic of
  • Fars
    • Shiraz, Fars, Iran, Islamic Republic of, 55318
      • Education Developmen Center
    • Shiraz, Fars, Iran, Islamic Republic of, 51318
      • Cardiology Ward Shiraz University of Medical Sciences
  • Outside Of The US
    • Shiraz, Outside Of The US, Iran, Islamic Republic of, 55318
      • Professor kojuri cardiology clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 39 years to 71 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Covid patients with recorded blood pressure before and after covid infection

Description

Inclusion Criteria:

• All COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery

Exclusion Criteria:

• Age under 18
• Hospital admission due to COVID-19
• Corticosteroid therapy,
• History of systemic inflammatory disease
• kidney disease
• liver disease
• Immunocompromised patients

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
hypertensive; Covid patients with exacerbated hypertension or new hypertension post covid	Diagnostic test: blood pressure measurement; Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
non hypertensive; Covid patients with no change in blood pressure pre and post covid	Diagnostic test: blood pressure measurement; Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change of blood pressure	any change in blood pressure level before and after covid infection	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
predictors of changes in blood pressure	history of any risk factor for cardiac disease, age, sex,	2 years

Collaborators and Investigators

• Sponsor: Shiraz University of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2020
• Primary Completion (Actual): December 28, 2022
• Study Completion (Actual): February 20, 2023

Study Registration Dates

• First Submitted: April 2, 2023
• First Submitted That Met QC Criteria: April 2, 2023
• First Posted (Actual): April 4, 2023

Study Record Updates

• Last Update Posted (Actual): April 4, 2023
• Last Update Submitted That Met QC Criteria: April 2, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: hypertension; blood pressure; covid-19
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Hypertension
• Other Study ID Numbers: IR.SUMS.MED.REC.1401

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Data are available based on rational request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No